SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (2418)2/19/1998 2:30:00 PM
From: Diamondcutter  Read Replies (2) of 7041
 
ZONA's lead banker issued a reply to the Wessels report today.

1. The Volpe Brown Whelan analyst stated on First Call that the only ZONA ongoing trial is a "large open label study" which includes patients continuing from the Phase III trials. He indicated 70% retention.

2. Through his discussions with a number of clinical investigators, there were no incidences of severe vomiting & nausea. Mild nasal congestion was the most frequent negative side effect.

3. Contrary to the Wessels report indicated that three dosage levels were being tested by ZONA. The company indicated that only two levels were tested (40 & 80mg) in Phase III, but three levels (40, 60, 80) were tested in the long-since-over Phase II in Germany.

For what it's worth...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News